These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 29435139)
1. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. Shen M; Asawa R; Zhang YQ; Cunningham E; Sun H; Tropsha A; Janzen WP; Muratov EN; Capuzzi SJ; Farag S; Jadhav A; Blatt J; Simeonov A; Martinez NJ Oncotarget; 2018 Jan; 9(4):4758-4772. PubMed ID: 29435139 [TBL] [Abstract][Full Text] [Related]
2. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. Zhang L; He M; Zhang Y; Nilubol N; Shen M; Kebebew E J Clin Endocrinol Metab; 2012 Mar; 97(3):E319-28. PubMed ID: 22170715 [TBL] [Abstract][Full Text] [Related]
3. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures. Sirenko O; Mitlo T; Hesley J; Luke S; Owens W; Cromwell EF Assay Drug Dev Technol; 2015 Sep; 13(7):402-14. PubMed ID: 26317884 [TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
5. Production of Uniform 3D Microtumors in Hydrogel Microwell Arrays for Measurement of Viability, Morphology, and Signaling Pathway Activation. Singh M; Close DA; Mukundan S; Johnston PA; Sant S Assay Drug Dev Technol; 2015 Nov; 13(9):570-83. PubMed ID: 26274587 [TBL] [Abstract][Full Text] [Related]
6. Identification of drug candidates and repurposing opportunities through compound-target interaction networks. Cichonska A; Rousu J; Aittokallio T Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153 [TBL] [Abstract][Full Text] [Related]
7. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243 [TBL] [Abstract][Full Text] [Related]
8. High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. Qosa H; Mohamed LA; Al Rihani SB; Batarseh YS; Duong QV; Keller JN; Kaddoumi A J Alzheimers Dis; 2016 Jul; 53(4):1499-516. PubMed ID: 27392852 [TBL] [Abstract][Full Text] [Related]
9. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403 [TBL] [Abstract][Full Text] [Related]
10. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329 [TBL] [Abstract][Full Text] [Related]
11. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
12. A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. Dey J; Kerwin WS; Grenley MO; Casalini JR; Tretyak I; Ditzler SH; Thirstrup DJ; Frazier JP; Pierce DW; Carleton M; Klinghoffer RA PLoS One; 2016; 11(6):e0158617. PubMed ID: 27359113 [TBL] [Abstract][Full Text] [Related]